Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis

Hepatology

Volumn 35, Issue 2, 2002, Pages 258-262

  Jones, E Anthony ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; URSODEOXYCHOLIC ACID;

BLOOD TOXICITY; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

EID: 0036151915     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.31607     Document Type: Article

References (51)

1. The peculiar autoimmunity of primary biliary cirrhosis
2. Immunopathogenesis of cholestatic autoimmune liver diseases
3. Molecular mimicry and primary biliary cirrhosis: Premises not promises
4. Natural history of primary biliary cirrhosis
5. Diminished survival in asymptomatic primary biliary cirrhosis: A prospective study
6. The ursodeoxycholic acid story in primary biliary cirrhosis
7. Ursodeoxycholic acid in primary biliary cirrhosis
8. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid
9. From a choleretic to an immunomodulator: Historical review of ursodeoxycholic acid as a medicament
10. Hepatoprotective properties of ursodeoxycholic acid
11. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy
12. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A metaanalysis
13. The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis
14. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid
15. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis: The results of a pilot study
16. Pilot study of low dose methotrexate treatment for primary biliary cirrhosis
17. Methotrexate therapy of primary biliary cirrhosis: 2 Yr study comparing two doses
18. Methotrexate therapy in primary biliary cirrhosis is of limited efficacy and accompanied by serious side effects
19. Low-dose methotrexate in primary biliary cirrhosis. Long-term results of a placebo-controlled trial
20. Methotrexate therapy for primary biliary cirrhosis: Five year follow up
21. Absence of pulmonary toxicity in primary biliary cirrhosis (PBC) treated with methotrexate and ursodiol
22. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss
23. The late results of long-term treatment of primary biliary cirrhosis by corticosteroids
24. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil
25. Mycophenolate mofetil and its mechanisms of action
26. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation
27. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity
28. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide
29. Immunosuppressive effect of mycophenolic acid
30. Antitumor and immunosuppressive effects of mycophenolic acid derivatives
31. Efficacy of mycophenolic acid for the treatment of psoriasis
32. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy and safety
33. Pharmacokinetics of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration
34. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review
35. Clinical pharmacokinetics of mycophenolate mofetil
36. From mice to man: The preclinical history of mycophenolate mofetil
37. Mycophenolate mofetil for transplantation: New drug, old problems?
38. Therapy of rheumatoid arthritis with mycophenolate mofetil
39. Mycophenolate mofetil in IBD patients
40. Taking aim at HIV replication
41. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
42. Effect of mycophenolic acid on Epstein-Barr virus infection of human lymphocytes
43. Mycophenolate mofetil: A unique immunosuppressive agent
44. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses
45. Mycophenolate mofetil: A promising new immunosuppressant that does not cause bone loss in the rat
46. Immunosuppressive treatment of chronic liver disease
47. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis
48. Mycophenolate mofetil: A potential long-term immunosuppressant treatment for primary biliary cirrhosis
49. Accurate prediction of death by serial determinations of galactose elimination capacity in primary biliary cirrhosis: A comparison with the Mayo model
50. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment
51. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center